Herbal compositions for the treatment of mucosal lesions
The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica . The compositions of the invention are of particular utility in the management of inflammatory mucosal diseases of both viral and non-viral origin.
1. A therapeutic composition for treating oral/or anal mucosal diseases comprising effective amounts of extracts from the species Echinacea purpurea, Sambucus nigra and Centella asiatica , wherein the composition reduces inflammation, and wherein the amount of each of the extracts is in an amount that, if added to a corresponding composition of the other two extracts, provides an increased effect on a marker of gingival inflammation, and wherein the combination provides a more than additive increased effect on the marker.
2. A therapeutic composition according to claim 1 for use in the treatment of diseases of the oral mucosa.
3. A therapeutic composition according to claim 1 for use in the treatment of diseases of the anal mucosa.
4. A therapeutic composition according to claim 1 , further comprising one or more extracts of plants selected from the group consisting of Uncaria tomentosa, Thymus vulgaris, Matricaria recutita, Salix alba, Calendula officinalis, Usnea barbata, Ligusticum porterii - osha, Gaultheria procumbens, Camellia sinensis, Vaccinium myrtillus, Melissa officinalis, Allium sativum, Camellia sinensis and Krameria triandra.
5. A therapeutic composition according to claim 4 , wherein the disease of the oral mucosa to be treated is selected from the group consisting of periodontal disease, gingivitis, aphthous ulceration, mechanical trauma, thermal trauma, lichen planus, bullous pemphigoid, pemphigus vulgaris and dermatitis herpetiformis, angular chelitis and recurrent herpes.
6. A therapeutic composition according to claim 5 , wherein the disease of the anal mucosa to be treated is selected from the group consisting of anal fissures, hemorrhoids and non-specific irritation.
7. A therapeutic composition according to claim 1 , wherein the composition inhibits one or more matrix metalloproteinases.
8. A therapeutic composition according to claim 7 , wherein the one or more matrix metalloproteinases to be inhibited are selected from the group consisting of matrix metalloproteinases 1-9.
9. A therapeutic composition according to claim 8 , wherein the matrix metalloproteinases that are inhibited are of matrix metalloproteinases of subclasses 1, 2, 8 and 9.
10. A therapeutic composition according to claim 9 , wherein the matrix metalloproteinase that is inhibited is of subclass 2.
11. A therapeutic composition according to claim 10 for use in the treatment of a disease of the oral mucosa selected from the group consisting of periodontal disease and aphthous ulceration.
12. A therapeutic composition according to claim 2 , wherein the disease of the oral mucosa to be treated is selected from the group consisting of periodontal disease, gingivitis, aphthous ulceration, mechanical trauma, thermal trauma, lichen planus, bullous pemphigoid, pemphigus vulgaris, dermatitis herpetiformis, angular chelitis and recurrent herpes.
13. A therapeutic composition according to claim 3 , wherein the disease of the anal mucosa to be treated is selected from the group consisting of anal fissures, hemorrhoids and non-specific irritation.
14. A therapeutic composition according to claim 1 , wherein the marker of gingival inflammation that is the proteolytic activity in gingival tissue of a matrix metalloproteinases of subclasses 1 to 9.
15. A therapeutic composition according to claim 1 , wherein the marker of gingival inflammation that is the proteolytic activity in gingival tissue of a matrix metalloproteinases of subclasses 2 or 9.